84394-97-8

Basic information

• Product Name: 1-(2-hydroxyethyl)-4-piperidone
• Synonyms: 1-(2-hydroxyethyl)-4-piperidone;1-(2-Hydroxyethyl)-4-piperidinone;Einecs 282-755-8
• CAS NO: 84394-97-8
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143.18362
• EINECS: 282-755-8
• Mol File: 84394-97-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 288.9°C at 760 mmHg
• Flash Point: 128.5°C
• Appearance: /
• Density: 1.109g/cm³
• Vapor Pressure: 0.000252mmHg at 25°C
• Refractive Index: 1.494
• PKA: 14.90±0.10(Predicted)
• CAS DataBase Reference: 1-(2-hydroxyethyl)-4-piperidone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-hydroxyethyl)-4-piperidone(84394-97-8)
• EPA Substance Registry System: 1-(2-hydroxyethyl)-4-piperidone(84394-97-8)

Safety Data

• Hazardous Substances Data: 84394-97-8(Hazardous Substances Data)

Usage

General Description

1-(2-hydroxyethyl)-4-piperidone is a chemical compound with the molecular formula C8H13NO2. It is commonly used as a pharmaceutical intermediate in the synthesis of various drugs and active pharmaceutical ingredients. The compound has a piperidone structure with a hydroxyethyl group attached to the nitrogen, giving it potential pharmacological properties. It is also used in the production of agrochemicals and as a building block in organic synthesis. Additionally, 1-(2-hydroxyethyl)-4-piperidone has been studied for its potential as a corrosion inhibitor and its ability to form complexes with metal ions. Overall, the compound has a wide range of applications in the pharmaceutical and chemical industries due to its versatile structure and properties.

InChI:InChI=1/C7H13NO2/c9-6-5-8-3-1-7(10)2-4-8/h9H,1-6H2

Upstream product

• 85997-58-6 N-(2-hydroxyethyl)-N-(3-methoxy-3-oxopropyl)-β-alanine 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.